Patents by Inventor Eugene R. Hickey

Eugene R. Hickey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors
    Patent number: 11919902
    Abstract: The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: wherein A, X, Y, Z, Q, R1, R2, R3, R4, R5, and n are described herein.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: March 5, 2024
    Assignee: HiberCell, Inc.
    Inventors: Johan Lindström, Lars Boukharta Persson, Madeleine Livendahl, Jenny Viklund, Tobias Ginman, Rickard Forsblom, Fredrik Rahm, Edward A. Kesicki, Kannan Karukurichi Ravi, Eugene R. Hickey, Markus K. Dahlgren, Aleksey I. Gerasyuto
  • ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE
    Publication number: 20240051948
    Abstract: The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): or pharmaceutically acceptable salts thereof wherein R, R1, R2, R3, R4, R5, R6, R7, and R8, are as defined herein. The disclosure also relates to methods of making and using compounds of Formula (I) or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: October 13, 2023
    Publication date: February 15, 2024
    Inventors: Erin Danielle ANDERSON, Sean Douglas ARONOW, Nicholas A. BOYLES, Surendra DAWADI, Eugene R. HICKEY, Thomas Combs IRVIN, Edward A. KESICKI, Gabrielle R. KOLAKOWSKI, Jennifer Lynn KNIGHT, Manoj KUMAR, Katelyn Frances LONG, Christopher Glenn MAYNE, Alfredo PICADO, Gerit Maria POTOTSCHNIG, Michael Brian WELCH, Tien WIDJAJA, Xiaohong CHEN, Nathan Edward WRIGHT, Hua-Yu WANG
  • Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease
    Patent number: 11878970
    Abstract: The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): or pharmaceutically acceptable salts thereof wherein R, R1, R2, R3, R4, R5, R6, R7, and R8, are as defined herein. The disclosure also relates to methods of making and using compounds of Formula (I) or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: May 26, 2022
    Date of Patent: January 23, 2024
    Assignee: PETRA PHARMA CORPORATION
    Inventors: Erin Danielle Anderson, Sean Douglas Aronow, Nicholas A. Boyles, Xiaohong Chen, Surendra Dawadi, Eugene R. Hickey, Thomas Combs Irvin, Edward A. Kesicki, Gabrielle R. Kolakowski, Jennifer Lynn Knight, Manoj Kumar, Katelyn Frances Long, Christopher Glenn Mayne, Johnathan Alexander McLean, Gerit Maria Pototschnig, Hua-Yu Wang, Michael Brian Welch, Tien Widjaja
  • Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease
    Patent number: 11873295
    Abstract: The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): or pharmaceutically acceptable salts thereof wherein R, R1, R2, R3, R4, R5, R6, R7, and R8, are as defined herein. The disclosure also relates to methods of making and using compounds of Formula (I) or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: May 2, 2022
    Date of Patent: January 16, 2024
    Assignee: PETRA PHARMA CORPORATION
    Inventors: Erin Danielle Anderson, Sean Douglas Aronow, Nicholas A. Boyles, Surendra Dawadi, Eugene R. Hickey, Thomas Combs Irvin, Edward A. Kesicki, Gabrielle R. Kolakowski, Jennifer Lynn Knight, Manoj Kumar, Katelyn Frances Long, Christopher Glenn Mayne, Alfredo Picado, Gerit Maria Pototschnig, Michael Brian Welch, Tien Widjaja, Xiaohong Chen, Nathan Edward Wright, Hua-Yu Wang
  • ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE
    Publication number: 20230286960
    Abstract: The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, W, X, Y, s, and Ring A are as described herein.
    Type: Application
    Filed: April 18, 2023
    Publication date: September 14, 2023
    Inventors: Erin Danielle ANDERSON, Sean Douglas ARONOW, Nicholas A. BOYLES, Markus K. DAHLGREN, Shulu FENG, Aleksey I. GERASYUTO, Eugene R. HICKEY, Thomas Combs IRVIN, Edward A. KESICKI, Anke KLIPPEL-GIESE, Jennifer Lynn KNIGHT, Gabrielle R. KOLAKOWSKI, Manoj KUMAR, Katelyn Frances LONG, Christopher Glenn MAYNE, David L. MCELLIGOTT, Johnathan Alexander MCLEAN, Loredana PUCA, Kannan Karukurichi RAVI, Daniel Lee SEVERANCE, Michael Brian WELCH, Tien WIDJAJA
  • Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
    Patent number: 11667651
    Abstract: The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: where A, B, R1, X1, X2, and W are described herein.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: June 6, 2023
    Assignee: HiberCell, Inc.
    Inventors: Johan Lindström, Lars Boukharta Persson, Jenny Viklund, Edward A. Kesicki, Eugene R. Hickey, Markus K. Dahlgren, Aleksey I. Gerasyuto
  • Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease
    Patent number: 11649227
    Abstract: The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, W, X, Y, s, and Ring A are as described herein.
    Type: Grant
    Filed: April 2, 2021
    Date of Patent: May 16, 2023
    Assignee: Petra Pharma Corporation
    Inventors: Erin Danielle Anderson, Sean Douglas Aronow, Nicholas A. Boyles, Markus K. Dahlgren, Shulu Feng, Aleksey I. Gerasyuto, Eugene R. Hickey, Thomas Combs Irvin, Edward A. Kesicki, Anke Klippel-Giese, Jennifer Lynn Knight, Gabrielle R. Kolakowski, Manoj Kumar, Katelyn Frances Long, Christopher Glenn Mayne, David L. McElligott, Johnathan Alexander McLean, Loredana Puca, Kannan Karukurichi Ravi, Daniel Lee Severance, Michael Brian Welch, Tien Widjaja
  • ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE
    Publication number: 20230147285
    Abstract: The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): or pharmaceutically acceptable salts thereof wherein R, R1, R2, R3, R4, R5, R6, R7, and R8, are as defined herein. The disclosure also relates to methods of making and using compounds of Formula (I) or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: September 30, 2022
    Publication date: May 11, 2023
    Inventors: Edward A. KESICKI, Eugene R HICKEY
  • ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE
    Publication number: 20230096175
    Abstract: The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): or pharmaceutically acceptable salts thereof wherein R, R1, R2, R3, R4, R5, R6, R7, and R8, are as defined herein. The disclosure also relates to methods of making and using compounds of Formula (I) or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: May 26, 2022
    Publication date: March 30, 2023
    Inventors: Erin Danielle ANDERSON, Sean Douglas ARONOW, Nicholas A. BOYLES, Xiaohong CHEN, Surendra DAWADI, Eugene R. HICKEY, Thomas Combs IRVIN, Edward A. KESICKI, Gabrielle R. KOLAKOWSKI, Jennifer Lynn KNIGHT, Manoj KUMAR, Katelyn Frances LONG, Christopher Glenn MAYNE, Johnathan Alexander MCLEAN, Gerit Maria POTOTSCHNIG, Hua-Yu WANG, Michael Brian WELCH, Tien WIDJAJA
  • Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
    Patent number: 11584763
    Abstract: The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: where A1, A2, G, R1, R2, R3, R4, and W are described herein.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: February 21, 2023
    Assignee: HiberCell, Inc.
    Inventors: Johan Lindström, Lars Boukharta Persson, Jenny Viklund, Rickard Forsblom, Tobias Ginman, Edward A. Kesicki, Eugene R. Hickey, Markus K. Dahlgren, Aleksey I. Gerasyuto
  • ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE
    Publication number: 20230017140
    Abstract: The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): or pharmaceutically acceptable salts thereof wherein R, R1, R2, R3, R4, R5, R6, R7, and R8, are as defined herein. The disclosure also relates to methods of making and using compounds of Formula (I) or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: May 2, 2022
    Publication date: January 19, 2023
    Inventors: Erin Danielle ANDERSON, Sean Douglas ARONOW, Nicholas A. Boyles, Surendra DAWADI, Eugene R. HICKEY, Thomas Combs IRVIN, Edward A. KESICKI, Gabrielle R. KOLAKOWSKI, Jennifer Lynn KNIGHT, Manoj KUMAR, Katelyn Frances LONG, Christopher Glenn MAYNE, Alfredo PICADO, Gerit Maria POTOTSCHNIG, Michael Brian WELCH, Tien WIDJAJA, Xiaohong CHEN, Nathan Edward WRIGHT, Hua-Yu WANG
  • ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE
    Publication number: 20230014445
    Abstract: The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with or pharmaceutically acceptable salts thereof wherein R, R1, R2, R3, R4, R5, R6, R7, and R8, are as defined herein. The disclosure also relates to methods of making and using compounds of Formula (I) or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: May 2, 2022
    Publication date: January 19, 2023
    Inventors: Erin Danielle ANDERSON, Sean Douglas ARONOW, Nicholas A. BOYLES, Xiaohong CHEN, Surendra DAWADI, Eugene R. HICKEY, Thomas Combs IRVIN, Edward A. KESICKI, Gabrielle R. KOLAKOWSKI, Jennifer Lynn KNIGHT, Manoj KUMAR, Katelyn Frances LONG, Christopher Glenn MAYNE, Alfredo PICADO, Gerit Maria POTOTSCHNIG, Hua-Yu WANG, Michael Brian WELCH, Tien WIDJAJA, Nathan Edward WRIGHT
  • Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
    Patent number: 11535635
    Abstract: The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: where A1, A2, G, R1, R2, R3, R4, and W are described herein.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: December 27, 2022
    Assignee: HiberCell, Inc.
    Inventors: Johan Lindström, Lars Boukharta Persson, Jenny Viklund, Rickard Forsblom, Tobias Ginman, Edward A. Kesicki, Eugene R. Hickey, Markus K. Dahlgren, Aleksey I. Gerasyuto
  • ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE
    Publication number: 20220372023
    Abstract: The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, W, X, Y, s, and Ring A are as described herein.
    Type: Application
    Filed: April 2, 2021
    Publication date: November 24, 2022
    Inventors: Erin Danielle ANDERSON, Sean Douglas ARONOW, Nicholas A. BOYLES, Markus K. DAHLGREN, Shulu FENG, Aleksey I. GERASYUTO, Eugene R. HICKEY, Thomas Combs IRVIN, Edward A. KESICKI, Anke KLIPPEL-GIESE, Jennifer Lynn KNIGHT, Gabrielle R. KOLAKOWSKI, Manoj KUMAR, Katelyn Frances LONG, Christopher Glenn MAYNE, David L. MCELLIGOTT, Johnathan Alexander MCLEAN, Loredana PUCA, Kannan Karukurichi RAVI, Daniel Lee SEVERANCE, Michael Brian WELCH, Tien WIDJAJA
  • AMINOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS
    Publication number: 20210317136
    Abstract: The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: where A, B, R1, X1, X2, and W are described herein.
    Type: Application
    Filed: December 21, 2018
    Publication date: October 14, 2021
    Inventors: Johan LINDSTRÖM, Lars Boukharta PERSSON, Jenny VIKLUND, Edward A. KESICKI, Eugene R. HICKEY, Markus K. DAHLGREN, Aleksey I. GERASYUTO
  • CHROMENOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS
    Publication number: 20210253600
    Abstract: The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: where A1, A2, G, R1, R2, R3, R4, and W are described herein.
    Type: Application
    Filed: December 21, 2018
    Publication date: August 19, 2021
    Inventors: Johan LINDSTRÖM, Lars Boukharta PERSSON, Jenny VIKLUND, Rickard FORSBLOM, Tobias GINMAN, Edward A. KESICKI, Eugene R. HICKEY, Markus K. DAHLGREN, Aleksey I. GERASYUTO
  • ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS
    Publication number: 20200331913
    Abstract: The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: wherein A, X, Y, Z, Q, R1, R2, R3, R4, R5, and n are described herein.
    Type: Application
    Filed: December 21, 2018
    Publication date: October 22, 2020
    Inventors: Johan LINDSTRÖM, Lars Boukharta PERSSON, Madeleine LIVENDAHL, Jenny VIKLUND, Tobias GINMAN, Rickard FORSBLOM, Fredrik RAHM, Edward A. KESICKI, Kannan Karukurichi RAVI, Eugene R. HICKEY, Markus K. DAHLGREN, Aleksey I. GERASYUTO
  • NATRIURETIC FUSION PROTEINS
    Publication number: 20100310561
    Abstract: Natriuretic peptide fusion proteins comprising natriuretic peptides linked to antibody Fc domains, nucleic acid molecules encoding the fusion proteins disclosed herein, expression vectors expressing said fusion proteins, pharmaceutical compositions comprising said fusion proteins, and methods for their therapeutic use are disclosed.
    Type: Application
    Filed: June 3, 2008
    Publication date: December 9, 2010
    Applicants: BOEHRINGER INGELHEIM INTERNATIONAL GMBH, SYNTONIX PHARMACEUTICALS, INC.
    Inventors: Keith Canada, Uwe Schoenbeck, Eugene R. Hickey, Adam Mezo, Kevin McDonnell
  • Cathepsin S inhibitors
    Patent number: 7465745
    Abstract: This invention relates to peptidyl compounds of the formulas (I) and (II) active as cathepsin S, a cysteine protease, inhibitors. The compounds are selective, reversible inhibitors of the cathepsin S are therefore useful in the treatment of autoimmune and other diseases. The invention also relates to processes for preparing such compounds and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: May 31, 2005
    Date of Patent: December 16, 2008
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Eugene R. Hickey, Wiemen Liu, Sanxing Sun, Yancey David Ward, Erick Richard Roush Young
  • Cathepsin S inhibitors
    Patent number: 7326719
    Abstract: This invention relates to peptidyl compounds of the formulas (I) and (II) active as cathepsin S, a cysteine protease, inhibitors. The compounds are selective, reversible inhibitors of the cathepsin S are therefore useful in the treatment of autoimmune and other diseases.
    Type: Grant
    Filed: March 1, 2004
    Date of Patent: February 5, 2008
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Eugene R. Hickey, Weimin Liu, Sanxing Sun, Yancey David Ward, Erick Richard Roush Young